Drug Profile
Research programme: respiratory disorder therapeutics - Pearl Therapeutics
Alternative Names: Formoterol/glycopyrrolate/mometasone - Nektar Therapeutics; PT002/PT009Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pearl Therapeutics
- Class Androstadienes; Corticosteroids; Ethanolamines; Phenethylamines; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA (Inhalation, Aerosol)
- 30 Nov 2013 Preclinical development is ongoing in USA
- 27 Jun 2013 Pearl Therapeutics has been acquired by AstraZeneca